• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LLS, Valor Biotherapeutics partner to advance novel therapy

LLS, Valor Biotherapeutics partner to advance novel therapy

May 30, 2013
CenterWatch Staff

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.

Valor's protein, IGN002, is a new class of biotherapeutics produced by fusing antibodies to tumor cell-killing cytokines to create a therapeutic agent with multiple properties in a single, genetically engineered molecule. The fusion molecule directs a targeted interferon alpha mediated cytotoxic effect on lymphoma cells leading to dramatically improved efficacy and safety profiles in preclinical studies. The clinical trial is anticipated to begin in late 2015.

Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the U.S. yet is a highly diverse disease with many subsets of patients. There are an estimated 530,000 people currently living with NHL or in remission.  In 2012, there were approximately 70,000 new cases of NHL diagnosed in the U.S. and about 19,000 NHL patients died in 2012 from their disease, which was unable to be controlled adequately with currently available therapeutic options.  Indolent or slowly progressing NHL is estimated to be about 40% of NHL cases in the U.S.

"Non-Hodgkin lymphoma, whether indolent or aggressive, continues to be a disease requiring more effective treatment options," said LLS chief mission officer Louis J. DeGennaro, Ph.D.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing